Reyon Pharmaceutical Co Ltd (102460) — Cash Flow Reinvestment Rate
Reyon Pharmaceutical Co Ltd (102460) has a Cash Flow Reinvestment Rate of 1.76x as of March 2025, reinvesting ₩4.25 Billion (capex ₩4.25 Billion plus investments ₩6.04 Million) from operating cash flow of ₩2.41 Billion. Check Reyon Pharmaceutical Co Ltd (102460) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Reyon Pharmaceutical Co Ltd Cash Flow Reinvestment Rate (2008–2023)
Historical reinvestment intensity for Reyon Pharmaceutical Co Ltd across 11 annual periods. Explore 102460 long-term investment intensity to see how much of total assets are deployed in long-term investments.
Annual Cash Flow Reinvestment Rate for Reyon Pharmaceutical Co Ltd (2008–2023)
Year-by-year capital reinvestment analysis for Reyon Pharmaceutical Co Ltd. For live market cap and broader valuation context, see 102460 market cap.
| Year | Reinvestment Rate | Total Reinvested (KRW) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2023 | 5.65x | ₩48.85 Billion | ₩8.65 Billion | ₩28.87 Billion | ▼ -57.4% |
| 2022 | 13.25x | ₩115.70 Billion | ₩8.73 Billion | ₩63.13 Billion | ▲ +30.1% |
| 2021 | 10.19x | ₩119.05 Billion | ₩11.68 Billion | ₩116.98 Billion | ▼ -37.1% |
| 2020 | 16.20x | ₩74.53 Billion | ₩4.60 Billion | ₩52.31 Billion | ▲ +120.5% |
| 2018 | 7.35x | ₩84.12 Billion | ₩11.45 Billion | ₩39.17 Billion | ▲ +144.8% |
| 2017 | 3.00x | ₩50.32 Billion | ₩16.76 Billion | ₩4.14 Billion | ▲ +186.4% |
| 2016 | 1.05x | ₩9.93 Billion | ₩9.47 Billion | ₩3.21 Billion | ▲ +334.7% |
| 2012 | 0.24x | ₩5.94 Billion | ₩24.65 Billion | ₩2.42 Billion | ▼ -37.8% |
| 2011 | 0.39x | ₩5.94 Billion | ₩15.34 Billion | ₩2.42 Billion | ▼ -1.2% |
| 2009 | 0.39x | ₩3.40 Billion | ₩8.68 Billion | ₩1.46 Billion | ▼ -41.6% |
| 2008 | 0.67x | ₩4.01 Billion | ₩5.99 Billion | ₩2.06 Billion | — |